AstraZeneca is donating $100,000 to the British Red Cross Pakistan Floods Appeal

Wednesday, 4 August 2010

The floods have left some 2.5m people in need of food, healthcare and shelter. The British Red Cross emergency Pakistan Floods Appeal is to help provide emergency relief to 20,000 families who have been affected by the flooding in the region.


Their work will include:

• Provision of hygiene kits and sanitation facilities to stem the spread of preventable diseases.
• Provision of safe drinking water to flood-affected families.


Aid is reaching thousands of families in the affected areas in Pakistan. Pakistan Red Crescent volunteers have already provided 20,000 people with food parcels and distributed other relief items, including tents, hygiene kits, jerry cans, kitchen sets, tarpaulin sheets and kerosene stoves.


In addition, AstraZeneca US is providing already donated hygiene kits via Americares to Pakistan.

Update:

The situation in Pakistan continues to worsen, with further flooding anticipated. The UN estimates that some 12 million people have been affected to date.

In addition to the recent $100,000 donation made by AZ to the British Red Cross Pakistan Floods appeal, the Red Cross have released stock from its Kuala Lumpur Disaster Response Centre, which continues to play an important role in disaster relief in the Asia Pacific region. The Centre was established in 2006 with $700,000 of funding from AstraZeneca and we have made further donations of over $400,000 since then to enable the facility to remain stocked with emergency supplies.

Supplies from Centre that are being distributed to people in need in Pakistan include 10,000 blankets, 3,000 hygiene kits, 600 jerry cans, 6,000 mosquito nets and 6,330 tarpaulins.

It is estimated that as many as 272,000 flood victims will receive aid provided by the International Red Cross and Red Crescent Movement during the early part of the relief effort.

How collaborative working can achieve the right safety profile

AZ scientists Mark Anderton and Ray Finlay discuss their role in re-designing an oncology compound

Achieving the right balance of benefit-risk is crucial; our job is to identify, characterise and eliminate molecules with negative benefit-risk balance as early and as quickly as possible.

Read the latest post on LabTalk


Read the latest blogs from our scientists working in our oncology portfolio

Oncology_compound_shows_THM 30 May 2014

Oncology compound shows how collaborative working can achieve the right safety profile

Driving open innovation across Asia THM 22 May 2014

AstraZeneca is driving open innovation across Asia